PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW127471View Pathway |
drug action
Trifluridine Action PathwayHomo sapiens
Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to idoxuridine and an active antiviral agent in ophthalmic solutions that is mainly used in the treatment of primary keratoxonjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity against Herpes simplex virus type 1 and 2.
The mechanism of action of trifluridine as an antiviral agent has not been fully elucidated, but appears to involve the inhibition of viral replication. Trifluridine gets incorporated into viral DNA during replication in replacement of thymidine, which leads to the formation of defective proteins and an increased mutation rate. Less Viral DNA is transported into the nucleus, therefore, less viral DNA is integrated into the host DNA. Less viral proteins produced, fewer viruses can form.
Trifluridine also mediates antineoplastic activities via this mechanism; following uptake into cancer cells, trifluridine is rapidly phosphorylated by thymidine kinase to its active monophosphate form. It is further phosphorylated into trifluridine triphosphate, which is readily incorporated into the DNA of tumour cells in place of thymidine bases to perturb DNA function, DNA synthesis, and tumour cell proliferation.
|
Creator: Ray Kruger Created On: March 07, 2023 at 14:17 Last Updated: March 07, 2023 at 14:17 |
PW144557View Pathway |
drug action
Trifluridine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 13:53 Last Updated: October 07, 2023 at 13:53 |
PW176178View Pathway |
Trifluridine Predicted Metabolism Pathway newHomo sapiens
Metabolites of Trifluridine are predicted with biotransformer.
|
Creator: Omolola Created On: November 30, 2023 at 10:11 Last Updated: November 30, 2023 at 10:11 |
PW128148View Pathway |
drug action
Triflusal Action PathwayHomo sapiens
Triflusal is a 2-acetoxy-4-trifluorobenzoic acid chemically related to acetylsalicylic acid. This drug has antithrombotic effects by inhibiting irreversibly the cycloxygenase-1 (COX-1) in the platelets. It is indicated as prophylaxis of thromboembolic disorders (prevention of strokes and myocardial infarction). Trifusal binds to the prostaglandin G/H synthase 1, this inhibits the production of thromboxane-B2 in cells. It also acts on many other cellular targets like NF kappa B, which is a gene expression regulatory factor for cycloxygenase-a and cytokines. In addition, this drug induces the production of nitric oxide by binding as an agonist to the nitric oxide synthase. The high level of nitric oxide results in vasodilatation. Trifusal is administered as an oral tablet.
|
Creator: Daphnee Created On: July 25, 2023 at 10:51 Last Updated: July 25, 2023 at 10:51 |
PW128147View Pathway |
drug action
Triflusal Action Pathway (new)Homo sapiens
Triflusal is a chemically related molecule similar to aspirin, used to treat thromboembolic diseases due to the antithrombotic effects. Triflusal is administered orally and acts as an antithrombotic anticoagulant that irreversibly inhibits cyclooxygenase-1(COX-1) also known as prostaglandin g/h synthase 1. By inhibiting COX-1 this prevents the formation of thromboxane B2 in platelets, unlike aspirin, it does not act on arachidonic acid in endothelial cells. The drug is metabolized into 2-hydroxy-4-trifluoromethyl benzoic acid, which also appears to have antiplatelet properties. Due to the anticoagulant and antiplatelet nature, herbs and supplements with similar activity should be avoided such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba.
|
Creator: Selena Created On: July 25, 2023 at 10:28 Last Updated: July 25, 2023 at 10:28 |
PW145839View Pathway |
drug action
Triflusal Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:47 Last Updated: October 07, 2023 at 16:47 |
PW121865View Pathway |
disease
Trifunctional Protein DeficiencyMus musculus
Trifunctional protein deficiency is a condition caused by mutations in the genes HADHA and HADHB. The enzyme affected is required to metabolize long-chain fatty acids, which makes a patients ability to convert fats to energy very difficult. This is exacerbated by periods without food. The symptoms associated with this disorder differ depending on when they appear in a patient. In infancy, symptoms would include lethargy, hypoglycaemia and hypotonia. Infants are also at higher risk for sudden death and heart problems. Later onset trifunctional protein deficiency symptoms also include hypotonia, but also include breakdown of muscle tissue and peripheral neuropathy. Treatment includes a low-fat, high-carbohydrate diet and avoiding fasting, as this can induce symptoms of this condition.
|
Creator: Ana Marcu Created On: September 10, 2018 at 15:50 Last Updated: September 10, 2018 at 15:50 |
PW122089View Pathway |
disease
Trifunctional Protein DeficiencyRattus norvegicus
Trifunctional protein deficiency is a condition caused by mutations in the genes HADHA and HADHB. The enzyme affected is required to metabolize long-chain fatty acids, which makes a patients ability to convert fats to energy very difficult. This is exacerbated by periods without food. The symptoms associated with this disorder differ depending on when they appear in a patient. In infancy, symptoms would include lethargy, hypoglycaemia and hypotonia. Infants are also at higher risk for sudden death and heart problems. Later onset trifunctional protein deficiency symptoms also include hypotonia, but also include breakdown of muscle tissue and peripheral neuropathy. Treatment includes a low-fat, high-carbohydrate diet and avoiding fasting, as this can induce symptoms of this condition.
|
Creator: Ana Marcu Created On: September 10, 2018 at 15:52 Last Updated: September 10, 2018 at 15:52 |
PW000521View Pathway |
disease
Trifunctional Protein DeficiencyHomo sapiens
Trifunctional protein deficiency is a condition caused by mutations in the genes HADHA and HADHB. The enzyme affected is required to metabolize long-chain fatty acids, which makes a patients ability to convert fats to energy very difficult. This is exacerbated by periods without food. The symptoms associated with this disorder differ depending on when they appear in a patient. In infancy, symptoms would include lethargy, hypoglycaemia and hypotonia. Infants are also at higher risk for sudden death and heart problems. Later onset trifunctional protein deficiency symptoms also include hypotonia, but also include breakdown of muscle tissue and peripheral neuropathy. Treatment includes a low-fat, high-carbohydrate diet and avoiding fasting, as this can induce symptoms of this condition.
|
Creator: WishartLab Created On: August 29, 2013 at 10:39 Last Updated: August 29, 2013 at 10:39 |
PW127311View Pathway |
disease
Trifunctional Protein DeficiencyHomo sapiens
Trifunctional protein deficiency is a condition caused by mutations in the genes HADHA and HADHB. The enzyme affected is required to metabolize long-chain fatty acids, which makes a patients ability to convert fats to energy very difficult. This is exacerbated by periods without food. The symptoms associated with this disorder differ depending on when they appear in a patient. In infancy, symptoms would include lethargy, hypoglycaemia and hypotonia. Infants are also at higher risk for sudden death and heart problems. Later onset trifunctional protein deficiency symptoms also include hypotonia, but also include breakdown of muscle tissue and peripheral neuropathy. Treatment includes a low-fat, high-carbohydrate diet and avoiding fasting, as this can induce symptoms of this condition.
|
Creator: Ray Kruger Created On: December 06, 2022 at 17:02 Last Updated: December 06, 2022 at 17:02 |